Navepegritide is a C-type natriuretic peptide (CNP) prodrug used to increase linear growth in pediatric patients with achondroplasia and open epiphyses. Achondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits endochondral ossification, resulting in multisystem complications including...
- Mechanism
- Curator reviewed · 5 references
Navepegritide is a prodrug consisting of a CNP moiety (identical to the 38 amino acid sequence of residues 89-126 of endogenous human CNP) transiently conjugated to two branched 20 kDa methoxy polyethylene glycol (mPEG) moieties via a proprietary TransCon Linker. Once administered, the TransCon linker undergoes auto-cleavage to release active CNP, which binds to NPR-B, stimulating the production of cGMP. This inhibits the mitogen-activated protein kinase (MAPK) signaling pathway, thereby antagonizing overactive FGFR3 signaling and promoting chondrocyte differentiation and proliferation to stimulate skeletal bone growth.
- Primary indication
- Navepegritide is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.Curator reviewed · 1 structured indication
- Formula / weight
- 45000.0 Da
- First approval
- United States, 2026
- Also known as
- TransCon CNP
- Code names
- ACP-015
- Brand names
Resolves to
What you can answer from here — as of April 21, 2026
Which drugs share a target with Navepegritide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account